Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
buyouts
Biotech
Painted into a corner, Mural agrees to Xoma buyout
The writing has been on the wall for Mural since April, when the cancer company’s IL-2 variant failed a phase 2 melanoma trial.
Darren Incorvaia
Aug 20, 2025 10:28am
Concentra scoops up near-defunct Allakos
Apr 2, 2025 5:05pm
Agiliti to go private in $2.5B buyout deal
Feb 27, 2024 11:19am
Permira takes CRO Ergomed private in £703M buyout deal
Sep 7, 2023 5:00am
Quince adopts 'poison pill' to fend off buyout, stock purchases
Apr 6, 2023 8:24am
Ginkgo scoops up AAV gene therapy capsid specialist StrideBio
Apr 5, 2023 7:00am
